Mustang Bio, Inc. (MBIO)
- Previous Close
0.2940 - Open
0.2887 - Bid 0.2685 x 100
- Ask 0.2822 x 200
- Day's Range
0.2700 - 0.2936 - 52 Week Range
0.1280 - 2.8130 - Volume
720,667 - Avg. Volume
11,127,429 - Market Cap (intraday)
10.418M - Beta (5Y Monthly) 1.96
- PE Ratio (TTM)
-- - EPS (TTM)
-2.7200 - Earnings Date Nov 12, 2024 - Nov 18, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
10.00
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.
www.mustangbio.comRecent News: MBIO
View MorePerformance Overview: MBIO
Trailing total returns as of 9/10/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MBIO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MBIO
View MoreValuation Measures
Market Cap
10.95M
Enterprise Value
7.76M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
31.75
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-0.14
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-105.16%
Return on Equity (ttm)
-1,191.31%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-32.06M
Diluted EPS (ttm)
-2.7200
Balance Sheet and Cash Flow
Total Cash (mrq)
4.27M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-11.5M